WealthPLAN Partners LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

WealthPLAN Partners LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 50,609 shares of the company’s stock, valued at approximately $1,022,000.

Several other hedge funds also recently modified their holdings of HIMS. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the second quarter worth approximately $111,000. Belpointe Asset Management LLC raised its position in shares of Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares during the period. Finally, Daiwa Securities Group Inc. bought a new position in shares of Hims & Hers Health in the 2nd quarter worth $142,000. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on HIMS shares. Piper Sandler restated a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Jefferies Financial Group raised their target price on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $16.10 on Wednesday. The company has a market capitalization of $3.46 billion, a PE ratio of -1,610.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74. The company has a 50-day simple moving average of $17.62 and a 200 day simple moving average of $17.05.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the business posted ($0.03) EPS. Hims & Hers Health’s quarterly revenue was up 51.8% compared to the same quarter last year. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 45,755 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total transaction of $1,050,992.35. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $769,540.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 45,755 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total value of $1,050,992.35. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $769,540.94. The disclosure for this sale can be found here. Insiders have sold a total of 755,159 shares of company stock worth $13,584,547 over the last ninety days. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.